DK1079851T3 - Anvendelse af anti-prolactinmidler til behandling af cancer - Google Patents

Anvendelse af anti-prolactinmidler til behandling af cancer

Info

Publication number
DK1079851T3
DK1079851T3 DK99921843T DK99921843T DK1079851T3 DK 1079851 T3 DK1079851 T3 DK 1079851T3 DK 99921843 T DK99921843 T DK 99921843T DK 99921843 T DK99921843 T DK 99921843T DK 1079851 T3 DK1079851 T3 DK 1079851T3
Authority
DK
Denmark
Prior art keywords
treatment
cancer
prolactin
agents
prolactin agents
Prior art date
Application number
DK99921843T
Other languages
Danish (da)
English (en)
Inventor
Wen Y Chen
Thomas E Wagner
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26772335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1079851(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Application granted granted Critical
Publication of DK1079851T3 publication Critical patent/DK1079851T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK99921843T 1998-05-12 1999-05-11 Anvendelse af anti-prolactinmidler til behandling af cancer DK1079851T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8512898P 1998-05-12 1998-05-12
US24604199A 1999-02-05 1999-02-05
PCT/US1999/010232 WO1999058142A1 (en) 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions

Publications (1)

Publication Number Publication Date
DK1079851T3 true DK1079851T3 (da) 2007-09-24

Family

ID=26772335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99921843T DK1079851T3 (da) 1998-05-12 1999-05-11 Anvendelse af anti-prolactinmidler til behandling af cancer

Country Status (11)

Country Link
US (2) US7115556B2 (enExample)
EP (2) EP2316467A1 (enExample)
JP (4) JP5259896B2 (enExample)
AT (1) ATE366114T1 (enExample)
AU (1) AU3895299A (enExample)
CA (1) CA2328520C (enExample)
DE (1) DE69936451T2 (enExample)
DK (1) DK1079851T3 (enExample)
ES (1) ES2288777T3 (enExample)
PT (1) PT1079851E (enExample)
WO (1) WO1999058142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070985A2 (en) * 2000-03-23 2001-09-27 Greenville Hospital System Bi-functional cancer treatment agents
CN100581529C (zh) * 2002-06-12 2010-01-20 莱雅公司 刚性形式的用硅氧烷聚合物和有机胶凝剂结构化的护理和/或美容化妆品组合物
WO2004054516A2 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US7507716B2 (en) * 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
WO2008028684A2 (en) * 2006-09-08 2008-03-13 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
EP2129793A1 (en) * 2007-03-20 2009-12-09 Institut National De La Sante Et De La Recherche Medicale Constitutively active mutants of the prolactin receptor
EP2167116A2 (en) * 2007-07-05 2010-03-31 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
US20110129873A1 (en) * 2008-04-30 2011-06-02 Monsanto Technology Llc Recombinant DNA Vectors for Expression of Human Prolactin Antagonists
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
CA2753804C (en) * 2009-02-26 2018-03-13 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2531211A4 (en) * 2010-02-03 2013-10-23 Orbis Health Solutions Llc METHOD FOR THE SENSITIZATION OF CELLS TO TREATMENT AGAINST CANCER
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833516A (en) * 1987-08-03 1989-05-23 International Business Machines Corporation High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6429186B1 (en) * 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
DE4231297A1 (de) * 1992-09-18 1994-03-24 Basf Ag Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen
WO1994019004A1 (en) 1993-02-19 1994-09-01 Genentech, Inc. Ligand antagonists for treatment of breast cancer
PT754682E (pt) * 1994-04-06 2002-03-28 Nippon Shinyaku Co Ltd Derivado de aminostilbazol e medicamento
DE19718721C2 (de) * 1997-05-02 1999-10-07 Siemens Ag DRAM-Zellenanordnung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
DE69936451D1 (de) 2007-08-16
EP2316467A1 (en) 2011-05-04
EP1079851B1 (en) 2007-07-04
DE69936451T2 (de) 2008-03-13
EP1079851A4 (en) 2004-03-17
JP5259896B2 (ja) 2013-08-07
JP5453355B2 (ja) 2014-03-26
JP2013224309A (ja) 2013-10-31
CA2328520C (en) 2013-06-25
EP1079851A1 (en) 2001-03-07
US20030022833A1 (en) 2003-01-30
PT1079851E (pt) 2007-10-08
JP2011079821A (ja) 2011-04-21
US7115556B2 (en) 2006-10-03
WO1999058142A9 (en) 2000-02-10
JP2002515404A (ja) 2002-05-28
JP2012020996A (ja) 2012-02-02
ES2288777T3 (es) 2008-01-16
AU3895299A (en) 1999-11-29
US20070060520A1 (en) 2007-03-15
ATE366114T1 (de) 2007-07-15
WO1999058142A1 (en) 1999-11-18
CA2328520A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
DE69936451D1 (de) Verwendung von anti-prolaktin agentien zur behandlung von krebs
PT1187918E (pt) Antagonistas de tek
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
ZA200606844B (en) Use for interleukin-33 (IL33) and the IL-33 receptor complex
IL145941A0 (en) Compositions and methods for cancer treatment by selectively inhibiting vegf
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
AP1869A (en) b2- Adrenergic receptor agonists.
DE60006280D1 (de) Beta 2 -adrenergische rezeptor-agonisten
EP1506285A4 (en) COMBINATIONS OF APOLLOTIC INDUCING LIGAND RESPECTOR AND OTHER THERAPEUTIC AGENTS RELATED TO A TUMOR NEKROSIS FACTOR
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
ATE261974T1 (de) Hoch-lipophile campothecin-derivate
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
ATE489103T1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs